MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy

Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC.
Source: Springer protocols feed by Cancer Research - Category: Cancer & Oncology Source Type: news

Related Links:

Thomas Hutson, DO, PharmD, reviews the case of a 70-year old woman who presents with symptomatic, metastatic clear cell renal cell carcinoma.08/21/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Publication date: Available online 21 August 2018Source: Life SciencesAuthor(s): Canbin Lin, Zuwei Li, Peijie Chen, Jing Quan, Xiang Pan, Liwen Zhao, Liang Zhou, Yulin Lai, Tao He, Weijie Xu, Jinling Xu, Xin Guan, Hang Li, Shangqi Yang, Yimin Hu, Yongqing LaiAbstractAimsIn adult population, the renal cell carcinoma (RCC) is one of the most common urological malignancies. It is meaningful to research for the molecular markers which are involved in the occurrence and development of RCC. Therefore, we concentrate on illuminating the role of microRNA-154-5p in progression of RCC and explore its prognostic values.Main methodsTh...
Source: Life Sciences - Category: Biology Source Type: research
All-cause mortality was significantly higher among renal cell carcinoma (RCC) patients who developed symptomatic venous thromboembolism (VTE) after undergoing nephrectomy and inferior vena cava (IVC) tumor thrombectomy (TT) accompanied by intravascular tumor thrombosis, a retrospective analysis showed.08/20/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Renal cell carcinoma (RCC) is the sixth most common diagnosis of cancer in men and the eighth in women in United States with an estimated 63,990 new cases and 14,400 deaths occurred in the 2017 [1]. In Europe, the incidence and the mortality of RCC are estimated to be 71,739 and 31,293 cases per years, respectively [2,3]
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
AbstractRenal mass biopsy is useful for the pathological diagnosis of a small renal mass difficult to distinguish fat-poor angiomyolipoma from renal cell carcinoma radiologically. Here, we report a young female case of a small renal mass suspected as fat-poor angiomyolipoma in imaging studies. The patient received a renal mass biopsy to obtain the correct pathological information. Unexpectedly, the pathological diagnosis was neuroendocrine tumor. She, finally, underwent a right radical nephrectomy as a curative treatment. This case indicates that the radiological findings of primary renal carcinoid tumor can be similar to ...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Authors: Zhang X, Chen L Abstract Renal cell carcinoma (RCC) and chronic kidney disease (CKD) are associated with hypoxia, but the effects of hypoxia on the process of angiogenesis in the two diseases are dramatically different. Some of matrix metalloproteinases (MMPs), such as MMP2 and MMP9, may have a role because they represent the most prominent family of proteinases associated with angiogenesis. In the present study, the differential response of human renal cell cancer cells (786-0), human renal tubular epithelial cells (HK-2) and human microvascular endothelial cells (HMEC-1) to hypoxia with regards to the ex...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Although renal cell carcinoma (RCC) represents only approximately 4% of adult malignancies in Europe, it displays the highest mortality rate of all urologic tumors with 40% of RCC patients dying from the disease [1]. In Germany, about 15,100 people are expected to be diagnosed with RCC in 2018 and an estimated 5,400 patients will die of kidney cancer each year [2]. As RCC does not immediately lead to clinical symptoms, about 20% to 30% of RCC patients present with advanced or metastatic disease (mRCC) at diagnosis [3] and about 20% of patients diagnosed with localized disease will subsequently develop metastases [4,5].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research
Renal cell carcinoma (RCC) has an estimated 63,990 new cases and 14,400 deaths in 2017 [1]. While the RCC survival rate had been traditionally poor, the 5-year survival rate had increased from 57% in 1987 to 1989 to 74% in 2006 to 2012 [1]. This improvement is likely due to 2 main factors: first is the diffuse use of imaging studies which resulted in increased detection of early-stage disease [2,3]; the other is the targeted therapy (TT) era for advanced RCC beginning at the end of 2005 with 7 antiangiogenic drugs and 2 mammalian target of rapamycin inhibitors approved from 2005 to 2016 by the Food and Drug Administration [4].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Clinical-Kidney cancer Source Type: research
ConclusionWe discovered that ISET is more suitable than the CSS for detecting CTCs in RCC patients. The presence of CTCs/CTMs in RCC patients correlated with higher TNM stages, suggesting that the presence of CTCs could be a prognostic marker in RCC patients.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
AbstractPurpose of the ReviewBrain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the manage...
Source: Current Neurology and Neuroscience Reports - Category: Neuroscience Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Carcinoma | Genetics | Kidney Cancer | Renal Cell Carcinoma | Vaccines